Phase I study of the safety and immunogenicity of AMA-1-C1/hydrogel + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Agatolimod (Primary) ; Aluminium hydroxide (Primary) ; Malaria vaccine (Primary)
- Indications Malaria
- Focus Adverse reactions; Pharmacodynamics
- 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
- 01 Oct 2006 New trial record.